Cargando…
An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer
The opioid receptor (OR) antagonist naltrexone inhibits estrogen receptor-α (ER) function in model systems. The goal of this study was to determine the clinical activity of naltrexone in patients with ER-positive metastatic breast cancer. Patients with hormone receptor positive metastatic breast can...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030534/ https://www.ncbi.nlm.nih.gov/pubmed/36441436 http://dx.doi.org/10.1007/s10637-022-01317-4 |